Navera Investment Management Ltd. Grows Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Navera Investment Management Ltd. increased its stake in Thermo Fisher Scientific by 0.6%, now owning approximately 664,893 shares valued at $269.5 million.
• A majority of the stock, about 89.23%, is held by institutional investors, showing significant confidence in Thermo Fisher Scientific.
• Recent analyst upgrades have raised the price target for Thermo Fisher Scientific, with Barclays setting a new target of $585, indicating strong growth expectations.

Navera Investment Management Ltd. grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 664,893 shares of the medical research company's stock after acquiring an additional 3,675 shares during the period. Thermo Fisher Scientific comprises 4.9% of Navera Investment Management Ltd.'s investment portfolio, making the stock its 12th biggest holding. Navera Investment Management Ltd. owned approximately 0.18% of Thermo Fisher Scientific worth $269,516,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in TMO. Brighton Jones LLC raised its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the period. Wedge Capital Management L L P NC grew its holdings in shares of Thermo Fisher Scientific by 957.5% in the first quarter. Wedge Capital Management L L P NC now owns 7,466 shares of the medical research company's stock valued at $3,715,000 after purchasing an additional 6,760 shares in the last quarter. Capital Investment Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 2.4% in the first quarter. Capital Investment Advisors LLC now owns 1,367 shares of the medical research company's stock valued at $680,000 after purchasing an additional 32 shares in the last quarter. Finally, NewSquare Capital LLC grew its holdings in shares of Thermo Fisher Scientific by 278.4% in the first quarter. NewSquare Capital LLC now owns 140 shares of the medical research company's stock valued at $70,000 after purchasing an additional 103 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a report on Thursday, October 2nd. Evercore ISI lifted their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an "outperform" rating in a report on Tuesday. HSBC restated a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $590.60.

Thermo Fisher Scientific Trading Down 0.8%

NYSE TMO opened at $539.54 on Wednesday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The stock has a market capitalization of $203.73 billion, a PE ratio of 31.21, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The firm has a 50 day moving average of $484.90 and a two-hundred day moving average of $447.60.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the business posted $5.37 EPS. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.